Models for the dispensing of anticancer medications are increasing. As models proliferate, the impact on oncology pharmacy, care delivery, and the patient experience can differ widely. Areas that may be affected include pharmacy operations and management, staffing, workflow, inventory, budget, patient education and monitoring, and more.
As the number of oral anticancer medications continues to grow, so do new challenges for education, delivery, and adherence. Dispensing requirements from manufacturers, payers, and regulators continue to change, as healthcare transitions to a value-based care environment.
Oncology pharmacy professionals, cancer programs and practices, hospitals, and health system pharmacists must stay informed on evolving dispensing models and how to effectively evaluate these for timely, effective, and safe delivery of therapies to patients with cancer.
ACCC is conducting this education program to understand how the current dispensing landscape is affecting delivery of oral therapies for patients with multiple myeloma. To better understand the impact on providers and patients, ACCC is conducting a series of focus group discussions.
This program seeks to gain deeper insight on the impact variations in dispensing models within hospitals, health systems, or practice groups has on patient-centered cancer care delivery, coordination of care as patients transition between care settings, and optimal pharmacy operations.
This program explores the implications of potential implementation of step therapy in Medicare Advantage plans.